Jøss, her skal det ikke mye til for å komme på topp 10 lista 
Vi trenger litt debatt, gravearbeid og noen oppkjøpsteorier - det er jo et spennende firma!
4 Likes
Litt mer graving og diskusjon hadde vært helt topp, men er nå greit at det ikke hauses så inni hampen som på andre biotechtråder.
Jeg slenger ut en påstand:
Bergen Bio er det mest undervurderte biotek på Oslo Børs, og at det ser ikke ut til at investorer på Tek ikke forstår, eller vil forstå det.
Kjør debatt 
Jeg har forsøkt å forstå bgbio og gitt opp.
Når jeg ikke forstår børsmeldingene til selskapet, eller abstraktene deres, og derfor ikke kan agere korrekt selv om jeg følger med så er det håpløst vanskelig for min del.
Så jeg følger med selskapet, men har gitt opp å forstå hva de driver med. Jeg tror det er bra, og handler kun teknisk.
Burde nok gjort mer av det samme selv!
Presentasjon er lagt ut:
Part 1 Utviklingsløp
Det er sikkert flere enn jeg som ikke alltid henger med når det gjelder hvor vi er i utviklingsløpet til en ny medisin/behandling. Om man leser denne linken så får man en grei innsikt i de forskjellige fasene og risikoen.
3 Likes
Part 2 FDA akselerert program
I denne posten tar vi for oss de forskjellige programmene som FDA har og hva som kreves for å komme raskere til mål
Fast Track
Qualifying criteria : A drug that is intended to treat a serious condition AND nonclinical or clinical data demonstrate the potential to address unmet medical need OR A drug that has been designated as a qualified infectious disease product
When to submit request: With IND or after. Ideally, no later than the pre-BLA or preNDA meeting
Timelines for FDA response: Within 60 calendar days of receipt of the request
Features: Actions to expedite development and review. Rolling review
Additional considerations : Designation may be rescinded if it no longer meets the qualifying criteria for fast track
Breakthrough Therapy
Qualifying criteria : A drug that is intended to treat a serious condition AND preliminary clinical evidence indicates that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over available therapies
When to submit request: With IND or after. Ideally, no later than the end-of-phase 2 meeting
Timelines for FDA response: Within 60 calendar days of receipt of the request
Features: Intensive guidance on efficient drug development. Organizational commitment. Rolling review. Other actions to expedite review
Additional considerations : Designation may be rescinded if it no longer meets the qualifying criteria for breakthrough therapy
Accelerated Approval
Qualifying criteria: A drug that treats a serious condition AND generally provides a meaningful advantage over available therapies AND demonstrates an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (IMM) that is reasonably likely to predict an effect on IMM or other clinical benefit (i.e., an intermediate clinical endpoint)
When to submit request: The sponsor should ordinarily discuss the possibility of accelerated approval with the review division during development, supporting, for example, the use of the planned endpoint as a basis for approval and discussing the confirmatory trials, which should usually be already underway
Timelines for FDA response: Not specified
Features: Approval based on an effect on a surrogate endpoint or an intermediate clinical endpoint that is reasonably likely to predict a drug’s clinical benefit
Additional considerations : Promotional materials. Confirmatory trials to verify and describe the anticipated effect on IMM or other clinical benefit. Subject to expedited withdrawal
Priority Review
Qualifying criteria: An application (original or efficacy supplement) for a drug that treats a serious condition AND, if approved, would provide a significant improvement in safety or effectiveness OR, Any supplement that proposes a labeling change pursuant to a report on a pediatric study under 505Ab OR, An application for a drug that has been designated as a qualified infectious disease product OR, Any application or supplement for a drug submitted with a priority review voucherd
When to submit request: With original BLA, NDA, or efficacy supplement
Timelines for FDA response: Within 60 calendar days of receipt of original BLA, NDA, or efficacy supplement
Features: Shorter clock for review of marketing application (6 months compared with the 10-month standard review)
Additional considerations : Designation will be assigned at the time of original BLA, NDA, or efficacy supplement filing
Bergenbio har oppnådd Fast Track
3 Likes
Part 3 Bergenbio språk
AA Accelerated approval
ADC Antibody drug conjugate
ALK Alkaline phosphatase
AML Acute myeloid leukemia
BLA Biologic license application
BT Breakthrough therapy
CAB Clinical advisory board
CBR Clinical benefit rate
CDx Companion diagnostic
CLIA Clinical Laboratory Improvement Amendments
CLL Chronic lymphocytic leukemia
CPI Checkpoint inhibitor
CR Complete response
CTL Cytotoxic T-lymphocytes
ECG Electrocardiogram
EGFR Epidermal growth factor receptor
ELISA Enzyme-linked immunosorbent assay
EMT Epithelial-to-mesenchymal transition
EU5 France, Germany, Italy, Spain, United Kingdom
FDA US Food and Drug Administration
GLP Good Laboratory Practice
IHC Immunohistochemistry
mAb Monoclonal antibody
MDS Myeloid dysplastic syndrome
NDA New drug application
NSCLC Non-small cell lung cancer
pAxl Phosphorylated
Axl Activated Axl
PD Progressive disease
PR Partial response
RCC Renal carcinoma
RP2D Recommended Phase II Dose
RTK Receptor tyrosine kinase
TAM Tyro, Axl, Mer (family of kinases)
TNBC Triple negative breast cancer
sAxl Soluble Axl
SD Stable disease
SoC Standard of Care
QTcF QT inverval, a measure of time in the heart’s electrical cycle
5 Likes
Part 4 Bergenbio Patenter
De fleste biotek start-up håper nok på en avtale med BP. I denne posten skal vi se hvordan Bergenbio har prøvd å sikre seg retten til bruk av teknologien.
Patentdatabasen som er benyttet er Justia (https://patents.justia.com/search?q=bergenbio) – denne søker kun for USA. Det kan forekomme flere patenter/publiseringer for Bergenbio, men det vil medføre et større stykke arbeid for min del.
Når en patent søkes om så går det opp til 18mnd før patent søknaden offentligjøres via « Application». Deretter så kan det gå mellom 2-5år før en patent blir innvilget. Det betyr at det som oppgis her mangler muligens det som faller inn under 18mnd perioden.
Oppsummert så har jeg funnet følgende:
8 innvilgede patenter
7 som kan bli godkjent når som helst…(se Part 5)
PHARMACEUTICALLY ACTIVE COMPOUNDS
Filed: December 23, 2015
Publication number: 20180029985 @ Publication date: February 1, 2018
Patent number : 10336702 @ Date of Patent : Jul 2, 2019
Inventors: Jason John SHIERS, John Paul WATTS, Stuart Thomas ONIONS, Mohammed Abdul QUDDUS, Joseph William WRIGGLESWORTH, Colin Peter SAMBROOK-SMITH, Alan NAYLOR, Derek LONDESBROUGH
The invention is directed to compounds of general formula (I), and pharmaceutical compositions containing such compounds. The compounds and compositions have valuable pharmaceutical properties. In particular, they may be used for the treatment of cancer. Novel intermediates and novel methods of preparation are also disclosed.
Methods of detecting Akt3 and administering Ax1 inhibitor https://patents.justia.com/patent/10317405
Filed: May 2, 2013
Publication Number : 20150119475
Patent number: 10317405 @ Date of Patent: June 11, 2019
Inventors : Jim Lorens (Bergen), Crina Tiron (Bergen)
The use of Akt3 as a biomarker for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject, and the use of Akt3 inhibitors to treat cancer is disclosed herein. Also disclosed are various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring Akt3 expression and/or activity.
ANTI-AXL ANTAGONISTIC ANTIBODIES
https://patents.justia.com/patent/10208121
Filed: December 18, 2015
Publication number: 20170349658 @ Publication date: December 7, 2017
Patent Grant number : 10208121 @ Date of Patent : Feb 19, 2019
Inventors: David Robert MICKLEM, Sergej KIPRIJANOV, James Bradley LORENS, Lavina AHMED, Linn Hodneland NILSSON, Tone SANDAL
Described are antibodies that specifically bind to the Axl protein and inhibit the interaction between Axl and the Axl-ligand, Gas6. Also disclosed are methods for the production and use of the anti-Axl antibodies.
ANTI-AXL ANTIBODIES
https://patents.justia.com/patent/9975953
Publication number: 20170107290 @ Publication date: April 20, 2017
Patent Grant number : 9975953 @ Date of Patent : May 22, 2018
Inventors: David Robert MICKLEM, Sergej KIPRIJANOV, Linn Hodneland NILSSON, Lavina AHMED, Hallvard HAUGEN
The present disclosure relates to antibodies which specifically bind to the Axl protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.
ANTI-AXL ANTIBODIES https://patents.justia.com/patent/9975954
Filed: June 18, 2015
Publication number: 20170129957 @ Publication date: May 11, 2017
Patent Grant number : 9975954 @ Date of Patent : May 22, 2018
Inventors : David Robert Micklem (Bergen), Sergej Kiprijanov (Oslo), Linn Hodneland Nilsson (Bergen), Lavina Ahmed (Bergen), Hallvard Haugen (Bergen)
This application is a national phase entry pursuant to 35 U.S.C. § 371 of International Application No. PCT/EP2015/063700, filed Jun. 18, 2015, which claims the benefit of priority of Great Britain Application No. 1410826.0, filed Jun. 18, 2014, each of which is incorporated by reference herein in its entirety for any purpose.
The present disclosure relates to antibodies which specifically bind to the Axl protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.
Use of kinase inhibitors
https://patents.justia.com/patent/20160339021
Filed: November 28, 2014
Publication Number : 20160339021 @ Publication Date : Nov 24, 2016
Patent number: 9801880 @ Date of Patent: October 31, 2017
Inventor: David Robert Micklem
The invention provides a compound for use for treating, preventing or managing a condition
associated with the activation, mutation and/or over-expression of one or more kinases, wherein if the condition is associated with Axl over-expression, it is also associated with the activation, mutation and/or over-expression of one or more other kinases, and wherein the compound has a structure according to formula (I) : wherein the symbols used in formula (I) are as defined herein.
Methods for Creating and Identifying Functional RNA Interference Elements
Type: Application
Filed: December 10, 2013
Publication number: 20140194322 @ Publication date: July 10, 2014
Patent Grant number : 9783801 @ Date of Patent : Oct 10, 2017
Inventors: DAVID MICKLEM, JAMES LORENS
The invention relates to the control of gene expression. Specifically, the invention provides compositions and methods for the production and use of recombinant nucleic acid molecules that have the ability to specifically downregulate an expressed target gene in vivo. In some aspects, the invention provides methods for producing a hairpin DNA molecule where part of the molecule is derived from an mRNA that is a target for a small interfering RNA (siRNA) derived from the hairpin. In other aspects, the invention provides synthetic hairpin adapter oligonucleotides that are used in the construction of siRNA-producing cassettes. In other aspects, the invention provides methods for testing for the presence or absence of specific inhibitory activity of an RNAi trigger molecule, and in still other aspects, the invention provides methods for identifying an active RNAi trigger molecule from a library of RNAi trigger molecules.
Methods for creating and identifying functional RNA interference elements
https://patents.justia.com/patent/8735064
Filed: December 23, 2008
Publication Number : 20110009281 @ Publication Date : Jan 13, 2011
Patent number: 8735064 @ Date of Patent: May 27, 2014
Inventors: David Micklem, James Lorens
The invention relates to the control of gene expression. Specifically, the invention provides compositions and methods for the production and use of recombinant nucleic acid molecules that have the ability to specifically downregulate an expressed target gene in vivo. In some aspects, the invention provides methods for producing a hairpin DNA molecule where part of the molecule is derived from an mRNA that is a target for a small interfering RNA (siRNA) derived from the hairpin. In other aspects, the invention provides synthetic hairpin adapter oligonucleotides that are used in the construction of siRNA-producing cassettes. In other aspects, the invention provides methods for testing for the presence or absence of specific inhibitory activity of an RNAi trigger molecule, and in still other aspects, the invention provides methods for identifying an active RNAi trigger molecule from a library of RNAi trigger molecules.
5 Likes
Part 5 Bergenbio Patent søknader
Under finner dere søknader som er under vurdering. De kan kommer når som helst.
Merknad: det kan ta mellom 2 -5 år før en patent blir innvilget.
https://patents.justia.com/patent/20200072839 Publication date: March 5, 2020
https://patents.justia.com/patent/20200010421 Publication date: January 9, 2020
https://patents.justia.com/patent/20190177419 Publication date: June 13, 2019
https://patents.justia.com/patent/20180371096 Publication date: December 27, 2018
https://patents.justia.com/patent/20180208989 Publication date: July 26, 2018
https://patents.justia.com/patent/20180153888 Publication date: June 7, 2018
https://patents.justia.com/patent/20170314077 Publication date: November 2, 2017
Her finner dere litt mer om hver av patentsøknadene.
METHOD
https://patents.justia.com/patent/20200072839
Filed: May 10, 2019
Publication number: 20200072839 @ Publication date: March 5, 2020
Type: Application
Inventors : Jim Lorens (Bergen), Crina Tiron (Bergen)
The use of Akt3 as a biomarker for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject, and the use of Akt3 inhibitors to treat cancer is disclosed herein. Also disclosed are various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring Akt3 expression and/or activity.
Pharmaceutically Active Compounds
https://patents.justia.com/patent/20200010421
Type: Application
Filed: May 15, 2019
Publication number: 20200010421 @ Publication date: January 9, 2020
Inventors: Jason John Shiers, John Paul Watts, Stuart Thomas Onions, Mohammed Abdul Quddus, Joseph William Wrigglesworth, Colin Peter Sambrook-Smith, Alan Naylor, Derek Londesbrough
The invention is directed to compounds of general formula (I) and pharmaceutical compositions containing such compounds. The compounds and compositions have valuable pharmaceutical properties. In particular, they may be used for the treatment of cancer. Novel intermediates and novel methods of preparation are also disclosed.
ANTI-AXL ANTAGONISTIC ANTIBODIES
https://patents.justia.com/patent/20190177419
Filed: December 19, 2018
Publication number: 20190177419 @ Publication date: June 13, 2019
Type: Application
Inventors: David Robert MICKLEM, Sergej KIPRIJANOV, James Bradley LORENS, Lavina AHMED, Linn Hodneland NILSSON, Tone SANDAL
Described are antibodies that specifically bind to the Axl protein and inhibit the interaction between Axl and the Axl-ligand, Gas6. Also disclosed are methods for the production and use of the anti-Axl antibodies.
ANTI-AXL ANTIBODIES
https://patents.justia.com/patent/20180371096
Filed : Apr 20, 2018
Type: Application
Publication number: 20180371096 @ Publication date: December 27, 2018
Inventors : David Robert MICKLEM (Bergen), Sergej KIPRIJANOV (Oslo), Linn Hodneland NILSSON (Bergen), Lavina AHMED (Bergen), Hallvard HAUGEN (Bergen)
This application is a continuation of U.S. application Ser. No. 15/318,028, filed Dec. 12, 2016, which is a national phase entry pursuant to 35 U.S.C. § 371 of International Application No. PCT/EP2015/063700, filed Jun. 18, 2015, which claims the benefit of priority of Great Britain Application No. 1410826.0, filed Jun. 18, 2014, each of which is incorporated by reference herein in its entirety for any purpose. The present disclosure relates to antibodies which specifically bind to the Axl protein. Also disclosed are methods for the production and use of the anti-Axl antibodies.
BIOMARKERS FOR CANCER
https://patents.justia.com/patent/20180208989
Filed: July 8, 2016
Publication number: 20180208989 @ Publication date: July 26, 2018
Type: Application
Inventors: Monica HELLESOY, Linn Hodneland NILSSON, David Robert MICKLEM
The use of PHGDH as a biomarker for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject, and the use of PHGDH modulators to treat cancer is disclosed herein. Also disclosed are various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring PHGDH expression and/or activity.
COMBINATION THERAPY WITH AXL INHIBITOR AND IMMUNE CHECKPOINT MODULATOR OR ONCOLYTIC VIRUS
https://patents.justia.com/patent/20180153888
Type: Application
Filed: May 27, 2016
Publication number: 20180153888 @ Publication date: June 7, 2018
Inventors: James Bradley LORENS, Gro GAUSDAL
An Axl inhibitor and one or more immune checkpoint (activity) modulators and/or one or more oncolytic viruses, for use in the prevention, treatment or management of cancer, wherein the Axl inhibitor and the one or more immune checkpoint (activity) modulators and/or the one or more oncolytic viruses are administered concurrently, separately or sequentially; compositions containing such components in combination; and methods of treating cancer in a patient by administering such components in combination.
SLFN11 AS BIOMARKER FOR AML
https://patents.justia.com/patent/20170314077
Filed: November 13, 2015
Publication number: 20170314077 @ Publication date: November 2, 2017
Type: Application
Inventors : David Robert MICKLEM (Bergen), Monica HELLESOY (Bergen), Linn Hodneland NILSSON (Bergen)
The use of Slfn11 as a biomarker for detecting the occurrence of epithlial-to-mesenchymal transition (EMT) in a subject, and the use of Slfn11 modulators to treat cancer is disclosed herein. Also disclosed are various methods for detecting the occurrence of epithelial-to-mesenchymal transition (EMT) in a subject by measuring Slfn11 expression and/or activity.
9 Likes
Part 6 In the Shoes of Investors
After information technology, biotechnology is increasingly recognized as the next wave in the knowledge-based economy.
Vi er nå inne i en femte teknologisk revolusjon basert på nanoteknologisk produksjon.
“Anyone, I would imagine, who has tried to create a biotech company knows just how important patents are. You learn this when you’re studying, and again at your first job, and if you haven’t done so before, you realize it the first time you meet potential investors .” (Mads Øvlisen, Chariman of the Board of Directors, Novo Nordsik).
Investors in biotechnology firms are well aware of the centrality of patents in the industry and will generally conduct a thorough due diligence prior to taking the decision to invest in a company. Their main concerns are generally two-fold.
Firstly, determining the company’s own IP position. In other words, does it fully own its IP? If not, has it obtained it through a licensing agreement and what are the terms and conditions of such an agreement? Is there likelihood of a dispute over ownership? Have the patents been granted? How wide is the geographical coverage? How broad is the protection and how efficient will they be to keep competitors from copying the product?
Secondly, investors will seek to determine whether the company will have freedom to operate, i.e. whether it will be able to commercialize the product without infringing on the IP rights of others. This will be important for investors to minimize risk of investing in a biotech company.
https://www.wipo.int/sme/en/documents/patents_biotech_fulltext.html
Patentporteføljen til Bergenbio virker sterk og de har flere søknader som enda ikke er godkjent – dette lover godt. I tillegg så har jeg registrert at de holder det de lover mhp guiding
12 Likes
Part 7 BergenBio pipeline
BergenBio oppgir følgende faser i deres programoversikt
Discovery
Lead optimisation
Preclincal
Phase 1
Phase 2
Phase 3
Ref Part 2 FDA akselerert program som jeg har postet over.
Når kan BergenBio søke Breakthrough designation?
Breakthrough designation applications are submitted as an amendment to the IND applications, usually prior to end of Phase II meeting
Når kan BergenBio søke Accelerated Approval?
The faster approval relies on use of surrogate endpoints.[1] Drug approval typically requires clinical trials with endpoints that demonstrate a clinical benefit, such as increased survival for cancer patients. Drugs with accelerated approval can initially be tested in clinical trials that use a surrogate endpoint, or something that is thought to predict clinical benefit. Surrogate endpoints typically require less time, and in the case of a cancer patient, it is much faster to measure a reduction in tumor size, for example, than overall patient survival.
Drugs approved under the FDA Accelerated Approval Program still need to be tested in clinical trials using endpoints that demonstrate clinical benefit, and those trials are known as phase 4 confirmatory trials. If the drug later proves unable to demonstrate clinical benefit to patients, the FDA may withdraw approval.[2][3]
Når kan BergenBio søke Priority Review?
Priority review vouchers are currently earned by pharmaceutical companies for the development and approval of drugs treating neglected tropical diseases, rare pediatric diseases, and “medical countermeasures” for terrorism. The voucher can be used for future drugs that could have wider indications for use, but the company is required to pay a fee (approximately $2.8 million) to use the voucher.
When seeking approval for a drug, manufacturers can apply to the FDA for priority review. This is granted when a drug is intended to treat a serious condition and would “provide a significant improvement in safety or effectiveness” over currently available treatments.[1] A priority review voucher can be used when a drug does not fit these requirements, but the company wishes to expedite the review process.[2]
Om vi ser på piplinen under til BergenBio så inneholder denne flere som ligger i slutten av fase 2. Jeg forventer at de søker om «Breakthrough Therapy» for noen av disse.
Pipeline 1 @ Phase 2
bemcentinib
Indication: NSCLC (Non-small cell lung cancer )
Combination: KEYTRUDA
Partner: Merck Inc
Bemcentinib met primary endpoint in first cohort of Phase II NSCLC study in combination with KEYTRUDA®
Pipeline 2 @ Phase 2
bemcentinib
Indication: NSCLC (Non-small cell lung cancer )
Combination: TARCEVA
Pipeline 3 @ Phase 2
bemcentinib
Indication: TNBC (Triple negative breast cancer)
Target: KEYTRUDA
Partner: Merck Inc.
Pipeline 4 @ Phase 2
bemcentinib
Indication: Melanoma
Combination: KEYTRUDA / TAFINLAR, MEKINIST
Partner: Bergen University Hospital
Pipeline 5 @ Phase 2 - Fast Track Designation
bemcentinib
Indication: AML (Acute Myeloid Leukaemia)
Combination: single agent / cytarabine, decitabine
Pipeline 6 @ Soon Phase 2
bemcentinib
Indication: NSCLC (Non-small cell lung cancer)
Combination: docetaxel
Partner: UTSW Medical Center
Pipeline 7 @ Preclinical
BGB149
Indication: Cancer
Target: AXL
Pipeline 8 @ Preclinical - Outlicensed
BGB601
Indication: Cancer
Target: AXL-ADC
Pipeline 9 @ Discovery
Indication: Cancer
Target: undisclosed
Veldig spennende pipeline og mange triggere framover.
8 Likes
Part 8 Pipeline 1 @ Phase 2 Non-small-cell lung cancer (NSCLC).
BergenBio’s partner Merck (** Keytruda)
Keytruda, is already one of the best-selling drugs in the world and is well on track to becoming the No. 1 drug by revenue within the next few years. Already been approved to treat a number of different cancer types, Keytruda is poised to play a crucial role in the company’s future sales growth.
Pipeline 1 @ Phase 2 Non-small-cell lung cancer (NSCLC).
-
For people with localized NSCLC, which means the cancer has not spread outside of the lung, the overall 5-year survival rate is 61%. For regional NSCLC, which means the cancer has spread outside of the lung to nearby areas, the 5-year survival rate is about 35%
-
If the cancer has spread to distant parts of the body, called metastatic lung cancer, the 5-year survival rate is 6%. But because of new effective treatments, this number is changing.
Professor Hani Gabra MD PhD, Chief Medical Officer of BerGenBio, commented: “I am impressed by these results that clearly demonstrate the durable clinical benefits in this difficult to treat low PD-L1 patient population. Importantly the patients that benefit most match gene signatures that predict poor prognosis and a lack of response to immunotherapy in NSCLC”.
Richard Godfrey, Chief Executive Officer of BerGenBio, commented: “I am delighted to see continued significant patient benefit from bemcentinib in combination with Keytruda. This is the first of three cohorts where we are evaluating this combination in previously treated lung cancer patients and I look forward to reporting data from these additional cohorts in the coming months.”
Current estimates predict that the global NSCLC market size will reach $43.7 billion by 2026
Spennende om BergenBio får Keytruda til å fungere bra…
5 Likes
Blir unektelig spennende å få mer data fra cohort b i nsclc. Senest i Juni vet vi mer her. Dersom en andel Keytruda refractory pssienter får effekt vil jeg tro det begynner å klø i fingrene til Merck. Kan ikke forstå annet en at de da vil ha Bemcentinib i sin cocktail.
4 Likes
En fersk aksjonærliste for BGBIO er tilgjengelig for Insider-medlemmer. Ikke Insider? Les mer og prøv gratis
Ny artikkel ute hvor forsknings-samarbeid mellom forskere i Sør-Korea, USA og Norge finner at BGB324 (bemcentinib) har effekt på magekreft (pre-klinisk), og foreslår dette som en mulig ny behandling (Obs. må prøves ut først):
8 Likes
Ny artikkel ute som foreslår at hemming av AXL (som bemcentinib hemmer) eller NFkB kan gjøre MPNST (en sjelden kreft som rammer celler rundt nerver) sensitiv mot andre kinase-hemmere og kjemoterapi:
6 Likes
Thanks for those Lars. Really think Bgbio is onto something with Bemcentinib. I also really think i don’t have anywhere near enough BGBIO shares…
3 Likes
Ny artikkel ute i Natur, en av de mest prestisjefylte journalene som finnes, har gjort pre-kliniske forsøk hvor de bekrefter at AXL oppregulerer PD-L1 (immunhemmer) og at behandling med R428 aka. BGB324 aka. bemcentinib blokkere denne oppreguleringen. Dette bekrefter at bemcentinib kan ha en viktig rolle i få immunforsvaret til å angripe kreften. Utrolig kult å finne denne artikkelen i Nature som er blant topp of the topp av journaler:
18 Likes
Ref over, men noe mere tekst for oss som ikke betaler…
https://www.google.ch/amp/s/www.oncozine.com/new-regulatory-pathway-may-boost-immunotherapy/amp/
New York City’s largest academic medical system, have discovered a pathway that regulates special immune system cells in lung cancer, suppressing them and allowing tumors to grow.
5 Likes